
Get exclusive money-saving offers and guides
Straight to your inbox
Posted
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Anteris Technologies Ltd is a medical devices business based in Australia. Anteris Technologies shares (AVR) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Anteris Technologies has a trailing 12-month revenue of around $10.3 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $3.03 - $7.5 |
---|---|
50-day moving average | $3.9758 |
200-day moving average | $5.1258 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.9895 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$3.92 on 2020-10-22
1 week (2021-01-11) | -25.33% |
---|---|
1 month (2020-12-18) | 3.16% |
3 months (2020-10-16) | -2.97% |
6 months (2020-07-17) | -8.84% |
1 year (2020-01-14) | N/A |
---|---|
2 years (2019-01-14) | N/A |
3 years (2018-01-14) | N/A |
5 years (2016-01-14) | N/A |
Revenue TTM | $10.3 million |
---|---|
Gross profit TTM | $8 million |
Return on assets TTM | -76.35% |
Return on equity TTM | -2.44% |
Profit margin | -2.28% |
Book value | 1.58 |
Market capitalisation | $23.2 million |
TTM: trailing 12 months
We're not expecting Anteris Technologies to pay a dividend over the next 12 months.
Anteris Technologies's shares were split on a 1:100 basis on 2 March 2020. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anteris Technologies shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Anteris Technologies shares which in turn could have impacted Anteris Technologies's share price.
Over the last 12 months, Anteris Technologies's shares have ranged in value from as little as $3.03 up to $7.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Anteris Technologies's is 0.9033. This would suggest that Anteris Technologies's shares are less volatile than average (for this exchange).
Anteris Technologies Ltd, a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd is based in Toowong, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.